Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strategic growth initiatives for SYFOVRE and EMPAVELI, with plans for market expansion and product development. While financial guidance is stable, new tools and education initiatives indicate a positive outlook. The Q&A session reveals optimism about market leadership and innovation, though some uncertainty exists around specific metrics. Overall, the strategic focus on growth and market expansion, coupled with a commitment to supporting patient access, suggests a positive sentiment, likely leading to a stock price increase in the short term.
Key Financial Performance
Total Revenue $200 million for Q4 2025 and $1 billion for the full year 2025. Full year revenue includes a one-time $275 million upfront payment from the Sobi royalty repurchase agreement.
SYFOVRE Net Product Revenue $155 million for Q4 2025 and $587 million for the full year 2025. Revenue was impacted by elevated free goods utilization throughout 2025.
EMPAVELI U.S. Net Product Revenue $35 million for Q4 2025 and $102 million for the full year 2025. The launch is progressing well, with early adoption and strong patient pipeline.
Operating Expenses $251 million in Q4 2025 compared to $239 million in Q4 2024. Full year 2025 operating expenses were consistent with 2024 levels.
Cash and Cash Equivalents $466 million at the end of 2025, providing substantial flexibility to fund the business to profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SYFOVRE: SYFOVRE continues to be a resilient and durable business with steady growth in total injections in 2025. Initiatives for 2027 include a prefilled syringe and OCT-F, an AI-enabled approach to visualize functional benefits.
EMPAVELI: EMPAVELI achieved more than 5% market penetration in its first full quarter post-launch for C3G and primary IC-MPGN. It has potential to be used by up to 50% of the estimated 5,000 U.S. patient population.
Geographic Atrophy (GA) Market: SYFOVRE continues to lead the GA market with strong payer coverage and a differentiated profile. Efforts are focused on physician engagement, data leadership, and innovation to support growth.
Nephrology Market: EMPAVELI is gaining traction in the nephrology market, with strong early adoption and favorable payer access. It is the only approved therapy for approximately 2/3 of patients with C3G and primary IC-MPGN in the U.S.
Financial Performance: Total revenue for 2025 was $1 billion, including a $275 million upfront payment from the Sobi royalty repurchase agreement. Operating expenses were consistent with 2024 levels, and the company ended the year with $466 million in cash.
Cost Management: Operating expenses in 2026 are expected to be modestly higher due to investments in pivotal trials and milestone payments, offset by a decrease in SG&A through operational efficiencies.
Pipeline Expansion: Pivotal trials for EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF) are underway. APL-9099, a first-in-class FcRn program, is advancing with an IND submission expected in the second half of 2026.
Next-Generation Strategy: SYFOVRE is being combined with APL-3007 to enhance efficacy and patient experience, with top-line data expected in 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
SYFOVRE revenue decline: Full year revenue for SYFOVRE was modestly down compared to 2024, largely due to elevated use of free goods, which impacted reported revenue.
Free goods utilization: Elevated free goods utilization through 2025 significantly impacted reported revenue for SYFOVRE. While third-party programs are resuming, the evolution of free goods utilization remains uncertain.
Gross-to-net adjustments: SYFOVRE adjustments in the fourth quarter trended above the mid-20% range, and gross-to-net is expected to increase to the high 20% range in 2026, reflecting market evolution.
Inventory management: A modest inventory reduction is expected in the first quarter of 2026, alongside seasonal dynamics such as Medicare reverifications, which could impact revenue.
EMPAVELI adoption challenges: While EMPAVELI achieved early market penetration, nephrology is known for conservative prescribing behavior and high evidentiary thresholds, which could slow broader adoption.
Operating expenses: Operating expenses are expected to increase modestly in 2026 due to investments in pivotal trials and milestone payments, which could pressure financials.
Convertible debt maturity: Approximately $94 million of convertible debt matures in September 2026, requiring thoughtful and disciplined financial management to address this obligation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SYFOVRE Revenue and Growth: SYFOVRE is expected to remain a stable and meaningful revenue stream through 2026. Initiatives such as a best-in-class prefilled syringe and OCT-F (AI-enabled visualization tool) are being advanced to support broader adoption and growth in 2027.
EMPAVELI Market Penetration and Growth: EMPAVELI achieved over 5% market penetration in its first full quarter post-launch for C3G and primary IC-MPGN. It is projected to potentially be used by up to 50% of the estimated 5,000 U.S. patient population. The company is focused on expanding engagement with prescribing physicians and deepening adoption across patient segments in 2026.
Pipeline Development: Pivotal trials for EMPAVELI are underway in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF). The company is also advancing APL-9099, a first-in-class FcRn program, with an IND submission expected in the second half of 2026.
Financial Guidance: Operating expenses in 2026 are expected to be modestly higher due to investments in pivotal trials and milestone payments, offset by a decrease in SG&A. Gross-to-net adjustments for SYFOVRE are expected to trend in the high 20% range, with net price stability anticipated through 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the breakdown of different indications throughout 2026 for EMPAVELI, including growth potential and challenges?
A:Cedric Francois stated that EMPAVELI is on a clear path to blockbuster status. For IC-MPGN, the epidemiology is approximately 5,000 patients in the U.S., split 50-50 between two indications. While exact breakdowns are not provided, there is important pickup and differentiation in the pediatric and post-transplant segments. They achieved more than 5% penetration after the first full quarter in Q4 and aim for up to 50% of the 5,000 patients at peak.
Q:Will there be equivalent penetration across different subpopulations of IC-MPGN and C3G?
A:Cedric Francois mentioned it is too early to provide specifics. He noted overlap between the two indications and emphasized the importance of covering all phenotypes in clinical trials.
Q:What should we focus on in the 5-year GALE data for SYFOVRE?
A:Cedric Francois highlighted the benefits and safety profile of SYFOVRE, showing that patients on treatment for 5 years can save up to 1.5 years of tissue. Caroline Baumal added that the extended trial data might lead to earlier treatment for geographic atrophy patients.
Q:How long will it take to reach 50% penetration for EMPAVELI, and what are the competitive dynamics?
A:Cedric Francois expects steady growth typical in rare diseases. EMPAVELI has unique positioning in the pediatric and IC-MPGN segments, with appreciation for its efficacy and safety profile. The post-transplant segment is also important due to the genetic nature of the disease.
Q:What are the variability factors for EMPAVELI in C3G in 2026, and will start forms or guidance be provided?
A:David Acheson explained that variability is due to the ultra-rare nature of the disease, with influxes of potential patients varying week to week. They will report revenues but not provide additional guidance on start forms.
Q:How important is the prefilled syringe (PFS) for SYFOVRE, and will it impact practice dynamics?
A:Cedric Francois and Caroline Baumal emphasized that the PFS is a practice-enabling innovation offering convenience and efficiency. It fits well into refrigerators and supports ease of clinical use, potentially driving renewed growth in 2027.
Q:What is the impact of improved co-pay dynamics for SYFOVRE on sales trajectory?
A:Timothy Sullivan noted that co-pay assistance is now available for geographic atrophy patients, representing an important advance. The impact on free goods dynamics is unclear, but it is expected to benefit patients who previously could not afford treatment.
Q:What are the expectations for enrollment in nephrology Phase III studies for EMPAVELI?
A:Cedric Francois stated it is too early to project enrollment but expressed excitement about the potential of EMPAVELI in FSGS and DGF, building on its success in C3G and IC-MPGN.
Q:What are the revenue trends for SYFOVRE in Q1 and 2026?
A:Timothy Sullivan explained that seasonal factors like weather and reverifications impact Q1. They expect modest growth over the year, with a more muted swing in Q1 compared to the previous year.
Q:Will the split favoring commercial doses for SYFOVRE continue in 2026?
A:Timothy Sullivan noted that the split favoring commercial doses was in line with expectations, and the co-pay assistance organization may have contributed to a small downtick in free goods.
Q:What are the expectations for the Phase II data of SYFOVRE in combination with APL-3007?
A:Cedric Francois explained that the GALLOP study aims to allow treatment every 3 months instead of 2 months and increase efficacy. The study uses siRNA to lower systemic C3 levels, giving SYFOVRE a stoichiometric advantage.
Q:What does the 50% penetration for C3G and IC-MPGN mean?
A:Cedric Francois clarified that up to 50% of the epidemiology could be treated with EMPAVELI. The strong launch and conservative epidemiology estimates contribute to confidence in reaching this penetration.
Q:Where is EMPAVELI in terms of the initial bolus of patients and steady-state growth?
A:David Acheson confirmed that the initial bolus of patients has transitioned to steady-state growth, which is expected to continue.
Q:How could the pipeline impact the timing of profitability for the company?
A:Timothy Sullivan stated that operating expenses are managed well, and revenue growth will drive profitability. New programs like the Beam program may increase costs but are factored into their projections.
Q:What progress has been made in helping SYFOVRE patients find the right insurance plans?
A:David Acheson explained that efforts were made to educate patients and offices about insurance plans, and the reverification process has been smooth. The impact on patient transitions is unclear.
Q:What is the company's commitment to providing free goods for SYFOVRE?
A:Cedric Francois emphasized the company's commitment to supporting patients who cannot afford co-pays, ensuring they do not go without treatment.
Q:What is the visibility into the patient pipeline for EMPAVELI in C3G and IC-MPGN?
A:Cedric Francois stated that the upstream pipeline of identified patients is larger than before the launch, indicating steady growth potential.
Q:Will the prefilled syringe for SYFOVRE expand the market or gain share?
A:Cedric Francois and Caroline Baumal believe the PFS will drive share gains and expand the market by improving workflow and ease of use for physicians.
Q:How will OCT-F technology impact the geographic atrophy market?
A:Cedric Francois and Caroline Baumal explained that OCT-F links structure to function, enabling earlier diagnosis and better patient management. It is expected to support SYFOVRE adoption and highlight the disease's impact.
Q:What are the competitive dynamics in the geographic atrophy market?
A:David Acheson noted that SYFOVRE holds 60% market share, supported by the 5-year GALE data. The company focuses on innovation and execution to maintain leadership.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or detailed breakdowns for certain questions, such as the exact penetration across subpopulations of IC-MPGN and C3G, the time to reach 50% penetration for EMPAVELI, and enrollment projections for nephrology Phase III studies. Additionally, they did not elaborate on the impact of co-pay dynamics on free goods or provide guidance on start forms for EMPAVELI.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI approach
APL
EMPAVELI efficacy
England Journal
Full
Journal Medicine
MPGN launch
New England
Physicians
adoption
approach benefit
base editing
biology
breadth depth
category
class base
class syringe
confidence
editing approach
efficiency
engagement physician
foundation
franchise
good utilization
milestone payment
peer
pillar
priority
program class
sham
status
term value
treatment paradigm
APLS Transcript
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call summary highlights strategic growth initiatives for SYFOVRE and EMPAVELI, with plans for market expansion and product development. While financial guidance is stable, new tools and education initiatives indicate a positive outlook. The Q&A session reveals optimism about market leadership and innovation, though some uncertainty exists around specific metrics. Overall, the strategic focus on growth and market expansion, coupled with a commitment to supporting patient access, suggests a positive sentiment, likely leading to a stock price increase in the short term.
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-3
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-2
APLS Slides
APLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
